These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 20525456

  • 1. Tecnetium-99m as alternative to produce somatostatin-labeled derivatives: comparative biodistribution evaluation with 111In-DTPA-octreotide.
    Melo IB, Ueda LT, Araujo EB, Muramoto E, Barboz MF, Mengatti J, Buchpiguel CA, Silva CP.
    Cell Mol Biol (Noisy-le-grand); 2010 May 10; 56(2):31-6. PubMed ID: 20525456
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D, Béhé M, Walter MA, Chen J, Powell P, Mikolajczak R, Mäcke HR.
    J Nucl Med; 2005 Sep 10; 46(9):1561-9. PubMed ID: 16157541
    [Abstract] [Full Text] [Related]

  • 3. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
    Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Forssell-Aronsson E.
    Cancer Biother Radiopharm; 2005 Apr 10; 20(2):231-6. PubMed ID: 15869461
    [Abstract] [Full Text] [Related]

  • 4. Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation.
    De K, Banerjee I, Misra M.
    Amino Acids; 2015 Jun 10; 47(6):1135-53. PubMed ID: 25743164
    [Abstract] [Full Text] [Related]

  • 5. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence.
    Decristoforo C, Mather SJ.
    Eur J Nucl Med; 1999 Aug 10; 26(8):869-76. PubMed ID: 10436200
    [Abstract] [Full Text] [Related]

  • 6. Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide.
    Maresca KP, Marquis JC, Hillier SM, Lu G, Femia FJ, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.
    Bioconjug Chem; 2010 Jun 16; 21(6):1032-42. PubMed ID: 20402463
    [Abstract] [Full Text] [Related]

  • 7. (99m)Tc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors.
    Dong C, Zhao H, Yang S, Shi J, Huang J, Cui L, Zhong L, Jin X, Li F, Liu Z, Jia B, Wang F.
    Mol Pharm; 2013 Aug 05; 10(8):2925-33. PubMed ID: 23768172
    [Abstract] [Full Text] [Related]

  • 8. Improved kit formulation for preparation of (99m)Tc-HYNIC-TOC: results of preliminary clinical evaluation in imaging patients with neuroendocrine tumors.
    Korde A, Mallia M, Shinto A, Sarma HD, Samuel G, Banerjee S.
    Cancer Biother Radiopharm; 2014 Nov 05; 29(9):387-94. PubMed ID: 25379612
    [Abstract] [Full Text] [Related]

  • 9. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ.
    Eur J Nucl Med; 2000 Jun 05; 27(6):628-37. PubMed ID: 10901448
    [Abstract] [Full Text] [Related]

  • 10. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
    Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, Moncayo R.
    J Nucl Med; 2003 May 05; 44(5):708-16. PubMed ID: 12732671
    [Abstract] [Full Text] [Related]

  • 11. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP, Breeman WA.
    J Nucl Med; 2003 Aug 05; 44(8):1315-21. PubMed ID: 12902423
    [Abstract] [Full Text] [Related]

  • 12. Preparation and biological evaluation of [(99m)Tc/EDDA/Tricine/HYNIC(0), BzThi(3)]-octreotide for somatostatin receptor-positive tumor imaging.
    Erfani M, Shafiei M, Mazidi M, Goudarzi M.
    Cancer Biother Radiopharm; 2013 Apr 05; 28(3):240-7. PubMed ID: 23464855
    [Abstract] [Full Text] [Related]

  • 13. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
    Maina T, Nock BA, Cordopatis P, Bernard BF, Breeman WA, van Gameren A, van den Berg R, Reubi JC, Krenning EP, de Jong M.
    Eur J Nucl Med Mol Imaging; 2006 Jul 05; 33(7):831-40. PubMed ID: 16568203
    [Abstract] [Full Text] [Related]

  • 14. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
    Cwikla JB, Mikolajczak R, Pawlak D, Buscombe JR, Nasierowska-Guttmejer A, Bator A, Maecke HR, Walecki J.
    J Nucl Med; 2008 Jul 05; 49(7):1060-5. PubMed ID: 18552141
    [Abstract] [Full Text] [Related]

  • 15. Synthesis, characterization, conformational analysis of a cyclic conjugated octreotate peptide and biological evaluation of (99m)Tc-HYNIC-His(3)-Octreotate as novel tracer for the imaging of somatostatin receptor-positive tumors.
    Behera A, Banerjee I, De K, Munda RN, Chattopadhayay S, Samanta A, Sarkar B, Ganguly S, Misra M.
    Amino Acids; 2013 Mar 05; 44(3):933-46. PubMed ID: 23090293
    [Abstract] [Full Text] [Related]

  • 16. Lanreotide labeled with 99mTc: preparation, preclinical testing and comparison with (111)In-DTPA-octreotide.
    Laznicek M, Laznickova A, Trejtnar F, Lorenc P, Varvarigou A, Bouziotis P, Archimandritis S.
    Anticancer Res; 2002 Mar 05; 22(4):2125-30. PubMed ID: 12174893
    [Abstract] [Full Text] [Related]

  • 17. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides.
    Vallabhajosula S, Moyer BR, Lister-James J, McBride BJ, Lipszyc H, Lee H, Bastidas D, Dean RT.
    J Nucl Med; 1996 Jun 05; 37(6):1016-22. PubMed ID: 8683294
    [Abstract] [Full Text] [Related]

  • 18. Introduction of an 8-aminooctanoic acid linker enhances uptake of 99mTc-labeled lactam bridge-cyclized α-MSH peptide in melanoma.
    Guo H, Miao Y.
    J Nucl Med; 2014 Dec 05; 55(12):2057-63. PubMed ID: 25453052
    [Abstract] [Full Text] [Related]

  • 19. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
    Grimes J, Celler A, Birkenfeld B, Shcherbinin S, Listewnik MH, Piwowarska-Bilska H, Mikolajczak R, Zorga P.
    J Nucl Med; 2011 Sep 05; 52(9):1474-81. PubMed ID: 21795364
    [Abstract] [Full Text] [Related]

  • 20. Somatostatin with 99mTc and biodistribution studies in rats.
    Acar C, Teksöz S, Unak P, Müftüler FZ, Medine EI.
    Cancer Biother Radiopharm; 2007 Dec 05; 22(6):748-54. PubMed ID: 18158765
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.